netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Reversing Retinal Degenerative Diseases: We’re One Step Closer

Degenerative disorders affecting the retinal pigment epithelium (RPE), such as age-related macular degeneration and autosomal recessive bestrophinopathy, can ultimately lead to blindness. Some of these life-changing disorders are the result of mutations in a single gene, called BEST1.

Although the genetic defect in BEST1 was identified almost two decades ago, its physiological role—how it does what it does, was unclear. Now, researchers from Columbia University and University of Rochester have used a novel approach to solve this mystery. Today, they published their pioneering study in the journal eLife

RPB Physician-Scientist Awardee Stephen H. Tsang, MD, PhD, of Columbia University, at work in his lab.

The researchers created a “disease-in-a-dish,” meaning that they coaxed skin cells taken from an adult patient first back into an embryonic-like state (called induced pluripotent stem cells, or iPSCs) and then into RPE cells to create a model of retinal degenerative disease. Then they assessed physiological properties of the RPE cells carrying normal or mutated BEST1 via innovative, interdisciplinary approaches to pinpoint the exact role of the BEST1 gene.

The researchers were also able to show that RPE cells that carry the BEST1 gene mutations, which are the same cells that are damaged by degenerative diseases, can have their damage reversed by providing healthy copies of the BEST1 gene (through viral gene supplementation, which uses a specially selected virus to “carry” new genes into the cells).

“Our team provided evidence that autosomal recessive bestrophinopathy is a ‘chloride channelopathy’ and is a treatable disorder,” said RPB Physician-Scientist Awardee Stephen H. Tsang, MD, PhD, Associate Professor of Ophthalmology and Associate Professor of Pathology and Cell Biology at Columbia University, and Tingting Yang, PhD, Assistant Professor of Pharmacology and Physiology at University of Rochester.

 

 

Related News: Feature Story, Gene Therapy, Macular Degeneration, Retina Disorders , Stem Cell Therapy, Top Story

RPB logo

Grant from Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer

Research to Prevent Blindness and Castle Biosciences are partnering to provide new opportunities for medical students to pursue ocular cancer research.

Read More

 
RPB logo

New Glaucoma Research Grant Available

Research to Prevent Blindness and Aerie Pharmaceuticals are partnering to provide grant opportunities to support novel research in glaucoma.

Read More

 
RPB logo

New Vision Science Research Grant for Students of Osteopathic Medicine

RPB and the AOCOO-HNS Foundation are launching a multi-year partnership to provide funding to increase research opportunities in vision science for students of osteopathic medicine.

Read More

 
Dr. Frans Vinberg

RPB Funding Helps Researchers Revive Light-Sensing Cells in Organ Donor Eyes

This ground-breaking research accomplishment will open new doors for research on neurodegenerative diseases like AMD.

Read More

 

Research to Prevent Blindness Opens Applications for up to $4.7 Million in Vision Research Grants

The awards offered cover a wide variety of topics in vision science, including glaucoma, age-related macular degeneration, ocular cancer, amblyopia, low vision, and many more.

Read More

 
Photo of eye
Watch The Video

Recording available: RPB webinar on Dry AMD and Geographic Atrophy

RPB grantees provide expert insight on geographic atrophy and dry AMD as part of the "Lunch & Learn" series.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.